Antithrombotic drug market will reach $24.3 billion in 2015

Friday 29 March 2013, Amsterdam

A new report predicts that the world antithrombotic drug market will reach revenue of $24.3 billion in 2015. That pharma market generated $22.7 billion in 2011, according to Antithrombotic Drugs: World Market 2013-2023, published in February 2013.We are a business information provider based in London, UK.

That study shows the overall market for antithrombotic drugs will expand steadily from 2013 to 2023. This expansion is due to rising disease prevalence and increases in healthcare spending in developing countries. The strength of the antithrombotic drug market stems from the high profile of the conditions associated with thrombotic disease, which require long term drug treatment, generating a high volume of long-term drug sales. That market holds great promise, for existing drugs and products under development.

Jennifer Taylor, a pharmaceutical industry analyst in visiongain, said: “The antithrombotic drug market is currently suffering from the loss of patent protection of the two leading drugs, Plavix and Lovenox. However, the market will soon recover with the establishment of novel oral anticoagulants on the market. Eliquis has recently received FDA approval and will soon capture a predominant share of the novel oral anticoagulant market. One major unmet need driving the antithrombotic drug market is that of an antidote for these novel oral anticoagulants. There are several antidotes in the R&D pipeline; when approved, those agents can look forward to a share of a $2 billion submarket.

“The establishment of those novel oral anticoagulants will change the face of the antithrombotic drug market. Currently, platelet aggregation inhibitors are the leading therapeutic class. However, the rapid growth in revenue of the direct thrombin inhibitor and direct factor Xa inhibitor therapeutic subclasses means anticoagulant drugs will become the leading group in that market within our forecast period.”

Our report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. It forecasts the world-level submarkets of platelet aggregation inhibitors, anticoagulants and fibrinolytics.

The study also forecasts the main subclasses of anticoagulant drug:

• Heparins
• Vitamin K antagonists
• Direct thrombin inhibitors
• Direct factor Xa inhibitors.

To 2023, the report forecasts revenues of leading products, including Plavix, Lovenox, Pradaxa, Pletal and Aggrenox, as well as sales of newer drugs – Effient, Brilinta, Xarelto and Eliquis. The work also forecasts national markets to 2023: the US, Japan, Germany, France, Italy, the UK, Spain (EU5), Brazil, Russia, India and China (BRIC). Other analyses include a review of R&D and research interviews with authorities in academia, medicine and industry.
Antithrombotic Drugs: World Market 2013-2023 adds to visiongain’s range of analytical reports on industries and markets in healthcare.